HAE Valuation

Haemonetics Corp

Add to Watchlist

Advanced Chart

54.540

+0.2(0.368%)1D

Overview
Forecast
Valuation
Earnings

HAE Relative Valuation

HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HAE is overvalued; if below, it's undervalued.

Historical Valuation

Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.93 is considered Undervalued compared with the five-year average of 22.94. The fair price of Haemonetics Corp (HAE) is between 95.51 to 158.39 according to relative valuation methord. Compared to the current price of 54.34 USD , Haemonetics Corp is Undervalued By 43.1%.

Relative Value

Fair Zone

95.51-158.39

Current Price：54.34

43.1%

Undervalued

10.93

Trailing

Forward

8.25

EV/EBITDA

Haemonetics Corp. (HAE) has a current EV/EBITDA of 8.25. The 5-year average EV/EBITDA is 14.37. The thresholds are as follows: Strongly Undervalued below 5.99, Undervalued between 5.99 and 10.18, Fairly Valued between 18.56 and 10.18, Overvalued between 18.56 and 22.74, and Strongly Overvalued above 22.74. The current Forward EV/EBITDA of 8.25 falls within the Undervalued range.

10.31

EV/EBIT

Haemonetics Corp. (HAE) has a current EV/EBIT of 10.31. The 5-year average EV/EBIT is 18.89. The thresholds are as follows: Strongly Undervalued below 7.71, Undervalued between 7.71 and 13.30, Fairly Valued between 24.47 and 13.30, Overvalued between 24.47 and 30.06, and Strongly Overvalued above 30.06. The current Forward EV/EBIT of 10.31 falls within the Undervalued range.

2.02

Haemonetics Corp. (HAE) has a current PS of 2.02. The 5-year average PS is 3.41. The thresholds are as follows: Strongly Undervalued below 1.29, Undervalued between 1.29 and 2.35, Fairly Valued between 4.47 and 2.35, Overvalued between 4.47 and 5.53, and Strongly Overvalued above 5.53. The current Forward PS of 2.02 falls within the Undervalued range.

10.32

P/OCF

Haemonetics Corp. (HAE) has a current P/OCF of 10.32. The 5-year average P/OCF is 12.91. The thresholds are as follows: Strongly Undervalued below -4.40, Undervalued between -4.40 and 4.26, Fairly Valued between 21.56 and 4.26, Overvalued between 21.56 and 30.21, and Strongly Overvalued above 30.21. The current Forward P/OCF of 10.32 falls within the Historic Trend Line -Fairly Valued range.

12.23

P/FCF

Haemonetics Corp. (HAE) has a current P/FCF of 12.23. The 5-year average P/FCF is 10.71. The thresholds are as follows: Strongly Undervalued below -10.40, Undervalued between -10.40 and 0.16, Fairly Valued between 21.27 and 0.16, Overvalued between 21.27 and 31.83, and Strongly Overvalued above 31.83. The current Forward P/FCF of 12.23 falls within the Historic Trend Line -Fairly Valued range.

Haemonetics Corp (HAE) has a current Price-to-Book (P/B) ratio of 2.97. Compared to its 3-year average P/B ratio of 4.68 , the current P/B ratio is approximately -36.62% higher. Relative to its 5-year average P/B ratio of 5.03, the current P/B ratio is about -41.01% higher. Haemonetics Corp (HAE) has a Forward Free Cash Flow (FCF) yield of approximately 7.14%. Compared to its 3-year average FCF yield of 3.10%, the current FCF yield is approximately 130.51% lower. Relative to its 5-year average FCF yield of 2.65% , the current FCF yield is about 169.69% lower.

2.97

P/B

Median3y

4.68

Median5y

5.03

7.14

FCF Yield

Median3y

3.10

Median5y

2.65

Competitors Valuation Multiple

The average P/S ratio for HAE's competitors is 2.51, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of 2.02, which is -19.79% above the industry average. Given its robust revenue growth of -4.40%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Inspire Medical Systems Inc

Alphatec Holdings Inc

Performance Decomposition

Market capitalization of HAE decreased by 27.84% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 336.17M to 321.39M.

The secondary factor is the Margin Expansion, contributed -7.19%to the performance.

Overall, the performance of HAE in the past 1 year is driven by Revenue Growth. Which is more sustainable.

-4.40%

336.17M → 321.39M

Revenue Growth

-7.19%

11.41 → 10.59

Margin Expansion

-16.25%

19.87 → 16.64

P/E Change

-27.84%